Value Bridge — MAIMONIDES MEDICAL CENTER
Current $-60M → Target $-33M (+$26.5M)
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-60.0M
Current EBITDA
$-33.5M
Target EBITDA
+$26.5M
Total Uplift
7
Value Levers
EBITDA Bridge — 7 Lever Model
Each lever shows gross impact, probability of achievement, and probability-weighted value.
Denial Rate Reduction
$0.0M
AR Acceleration
$0.0M
Coding Accuracy Uplift
$6.0M
Payer Mix Optimization
$14.4M
Cost to Collect Reduction
$4.8M
Clean Claim Improvement
$3.6M
Volume & Rate Growth
$24.0M
What This Means
The 7-lever model projects a 0% EBITDA uplift from $-60M to $-33M. The highest-impact lever is Volume & Rate Growth at $9.6M probability-weighted.
IC talking point: "We see $27M in annual EBITDA improvement, primarily from volume & rate growth. At an 11x multiple, this represents $292M in equity value creation."